178 related articles for article (PubMed ID: 27815086)
1. Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
Stewart GD; Aitchison M; Bex A; Larkin J; Lawless C; Méjean A; Nathan P; Oades G; Patard JJ; Paul J; Ravaud A; Escudier B;
Eur Urol; 2017 Jun; 71(6):845-847. PubMed ID: 27815086
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
3. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
[TBL] [Abstract][Full Text] [Related]
4. The role of cytoreductive surgery in the era of targeted agents.
Noe A; Stewart GD; Bex A
Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
[TBL] [Abstract][Full Text] [Related]
5. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Gurram S; Al Harthy M; Ball MW
Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases.
Arora S; Sood A; Dalela D; Tang HJ; Patel A; Keeley J; Trinh QD; Rogers CG; Menon M; Abdollah F
Eur Urol; 2019 Feb; 75(2):352-353. PubMed ID: 30420256
[No Abstract] [Full Text] [Related]
7. Complete responses in advanced renal cell carcinoma: utopia or real chance?
Verzoni E; Garanzini E; Procopio G
Clin Exp Nephrol; 2013 Feb; 17(1):151-2. PubMed ID: 23292180
[No Abstract] [Full Text] [Related]
8. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
9. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?
Kokorovic A; Rendon RA
Curr Opin Support Palliat Care; 2019 Sep; 13(3):255-261. PubMed ID: 31082942
[TBL] [Abstract][Full Text] [Related]
11. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
12. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?
Grant M; Szabados B; Kuusk T; Powles T; Bex A
Curr Opin Urol; 2020 Jan; 30(1):36-40. PubMed ID: 31789991
[TBL] [Abstract][Full Text] [Related]
14. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y
Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
[TBL] [Abstract][Full Text] [Related]
16. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
[TBL] [Abstract][Full Text] [Related]
18. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
Ghandour RA; Singla N; Margulis V
Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
[TBL] [Abstract][Full Text] [Related]
19. Role of cytoreductive surgery in the era of immunotherapy.
Isali I; Braun A; Bukavina L; Psutka SP
Curr Opin Urol; 2022 Nov; 32(6):618-626. PubMed ID: 36081404
[TBL] [Abstract][Full Text] [Related]
20. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
Dariane C; Timsit MO; Méjean A
Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
